Jonathan Lo, MD
Ophthalmology · Honolulu, HINPI 1285096289
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,218 of the $4,076 with a category attached, or 79.0%. 16 manufacturers reported payments, led by Alcon at 32.3% of the total. 2025 is the largest year on record at $1,384, 9.5 times the $146 reported in 2019.
Across 109 payments — averaging $37.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- AbbVie$656
- Regeneron Healthcare Solutions, Inc.$287
- Bausch & Lomb Americas Inc.$266
- Sun Pharmaceutical Industries Inc.$263
- Sight Sciences, Inc.$225
- plus $1K from 10 others
What the payments were for
- Food & beverage$3,21879%
- Gifts$190%
- Other$83821%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 14 | $1,315 |
| AbbVie(2 entities) | 29 | $656 |
| Regeneron Healthcare Solutions, Inc. | 6 | $287 |
| Bausch & Lomb Americas Inc. | 13 | $266 |
| Sun Pharmaceutical Industries Inc. | 10 | $263 |
| Sight Sciences, Inc. | 6 | $225 |
| Aerie Pharmaceuticals, Inc. | 3 | $192 |
| Genentech USA, Inc. | 3 | $190 |
| Tarsus Pharmaceuticals, Inc. | 7 | $173 |
| Kala Pharmaceuticals, Inc. | 7 | $152 |
| Rxsight Inc | 1 | $120 |
| Novartis | 5 | $108 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $44 |
| Amgen | 1 | $34 |
| Oyster Point Pharma, Inc. | 1 | $32 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,076 in reported general payments places this provider in the 60th percentile of 120 ophthalmology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 811 | $1,045,269 |
| XiidraLifitegrast | 95 | $128,888 |
| LumiganBimatoprost | 101 | $75,150 |
| CequaCyclosporine | 49 | $47,485 |
| ProlensaBromfenac Sodium | 71 | $32,680 |
| VyzultaLatanoprostene Bunod | 56 | $30,741 |
| MieboPerfluorohexyloctane/Pf | 22 | $30,298 |
| Alphagan PBrimonidine Tartrate | 43 | $23,515 |
| RocklatanNetarsudil Mesylat/Latanoprost | 20 | $16,788 |
| CombiganBrimonidine Tartrate/Timolol | 24 | $13,098 |
| Prednisolone Acetate | 119 | $10,004 |
| RhopressaNetarsudil Mesylate | 16 | $9,819 |
| Travoprost | 41 | $9,519 |
| Latanoprost | 446 | $8,341 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 21 | $7,833 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $656 | $1,157,032979 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $266 | $189,927173 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $263 | $47,48549 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $44 | $34,30282 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $192 | $26,60736 claims |
| AlconSimbrinza | $1,315 | $7,83321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 120 ophthalmology providers in Hawaii.
Other ophthalmology in Honolulu
- Neda NikpoorHonolulu$293K
- Carlton YuenHonolulu$175K
- Alan FaulknerHonolulu$135K
- Michael BennettHonolulu$108K
- Jeffrey PetersonHonolulu$77K
- Rupa WongHonolulu$72K
- Jon PortisHonolulu$20K
- Tyrie JenkinsHonolulu$19K
- John OlkowskiHonolulu$15K
- Claudia HootenHonolulu$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.